Reuters logo
BRIEF-VBI Vaccines announces FDA acceptance of investigational NDA for sci-b-vac phase 3 clinical program
August 30, 2017 / 12:11 PM / 3 months ago

BRIEF-VBI Vaccines announces FDA acceptance of investigational NDA for sci-b-vac phase 3 clinical program

Aug 30 (Reuters) - VBI Vaccines Inc

* VBI Vaccines announces FDA acceptance of investigational new drug application for SCI-B-VAC(R) phase 3 clinical program

* VBI Vaccines Inc - ‍expects to initiate enrollment in a phase 3 clinical program later in second half of 2017 in U.S., Europe and Canada​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below